Technology
Endevica Bio's primary molecule TCMCB07 is an MC4R antagonist that has shown efficacy in multiple models of cachexia. Pre-clinical animal trial results show significant lean muscle mass gain (e.g. a reversal of the cachectic condition) during the administration of the drug. The results have been synchronous across multiple cachexia-inducing insult classes. Endevica Bio's technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.